These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2857104)

  • 1. Long term treatment of acromegaly with a long acting analogue of somatostatin.
    Ch'ng LJ; Sandler LM; Kraenzlin ME; Burrin JM; Joplin GF; Bloom SR
    Br Med J (Clin Res Ed); 1985 Jan; 290(6464):284-5. PubMed ID: 2857104
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of high dose somatostatin analogue on growth hormone concentrations in acromegaly.
    Sandler LM; Burrin JM; Joplin GF; Bloom SR
    Br Med J (Clin Res Ed); 1988 Mar; 296(6624):751-2. PubMed ID: 2894886
    [No Abstract]   [Full Text] [Related]  

  • 3. [Advancing acromegaly with low growth hormone levels. Influence of an analog of somatostatin administered in continuous subcutaneous infusion].
    Leblanc H; Lebouc Y; Saltiel H; Thote A; Passa P
    Presse Med; 1988 Feb; 17(4):164. PubMed ID: 2894669
    [No Abstract]   [Full Text] [Related]  

  • 4. [Long-term treatment of acromegaly with a somatostatin analog].
    Vest S
    Ugeskr Laeger; 1987 Aug; 149(34):2263. PubMed ID: 2897734
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of resistant acromegaly with a long-acting somatostatin analogue (SMS 201-995).
    Barnard LB; Grantham WG; Lamberton P; O'Dorisio TM; Jackson IM
    Ann Intern Med; 1986 Dec; 105(6):856-61. PubMed ID: 2877605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
    N Engl J Med; 1986 May; 314(21):1390-2. PubMed ID: 2871490
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.
    Lamberts SW; Uitterlinden P; Verschoor L; van Dongen KJ; del Pozo E
    N Engl J Med; 1985 Dec; 313(25):1576-80. PubMed ID: 2866445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective and lasting growth-hormone suppression in active acromegaly with oral administration of somatostatin analogue SMS 201-995.
    Williams G; Ball JA; Burrin JM; Joplin GF; Bloom SR
    Lancet; 1986 Oct; 2(8510):774-8. PubMed ID: 2876235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapy with somatostatin analogues for acromegaly.
    Sassolas G
    Eur J Endocrinol; 1995 Dec; 133(6):675-7. PubMed ID: 8548050
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of acromegaly with a somatostatin analog in a patient with McCune-Albright syndrome.
    Geffner ME; Nagel RA; Dietrich RB; Kaplan SA
    J Pediatr; 1987 Nov; 111(5):740-3. PubMed ID: 2889819
    [No Abstract]   [Full Text] [Related]  

  • 11. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term management of acromegaly with sandostatin.
    Tolis G
    Horm Res; 1988; 29(2-3):112-4. PubMed ID: 2900189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.
    Bandgar TR; Sarathi V; Shivane V; Bansode N; Menon PS; Shah NS
    J Postgrad Med; 2010; 56(1):7-11. PubMed ID: 20393242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose and frequency titration of somatostatin analogues in the treatment of acromegaly - an injection of expediency?
    James RA; Gilroy J
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):11-3. PubMed ID: 11167919
    [No Abstract]   [Full Text] [Related]  

  • 15. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.
    Comi RJ; Gorden P
    J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin octapeptide (SMS 201-995) in the medical treatment of acromegaly.
    Wass JA; Lytras N; Besser GM
    Scand J Gastroenterol Suppl; 1986; 119():136-40. PubMed ID: 2876497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial.
    Giustina A; Bonadonna S; Bugari G; Colao A; Cozzi R; Cannavo S; de Marinis L; Degli Uberti E; Bogazzi F; Mazziotti G; Minuto F; Montini M; Ghigo E
    Eur J Endocrinol; 2009 Aug; 161(2):331-8. PubMed ID: 19465485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.